These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16682734)

  • 1. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Calvo E; Baselga J
    J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
    Edelman MJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 12. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
    Tsao AS; Papadimitrakopoulou V
    Clin Lung Cancer; 2013 Jul; 14(4):311-21. PubMed ID: 23582282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.
    Bencardino K; Manzoni M; Delfanti S; Riccardi A; Danova M; Corazza GR
    Intern Emerg Med; 2007 Mar; 2(1):3-12. PubMed ID: 17551677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of growth factor signalling.
    Wakeling AE
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
    Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
    PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
    Zalcman G
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
    [No Abstract]   [Full Text] [Related]  

  • 17. Lung cancer in never smokers: change of a mindset in the molecular era.
    Lee YJ; Kim JH; Kim SK; Ha SJ; Mok TS; Mitsudomi T; Cho BC
    Lung Cancer; 2011 Apr; 72(1):9-15. PubMed ID: 21272954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race, gender and mutations in the prediction of anti-EGFR activity.
    Jimeno A
    Future Oncol; 2005 Apr; 1(2):201-4. PubMed ID: 16555991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of EGFR targeted therapy.
    Baselga J
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):218-9. PubMed ID: 16224409
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.